Occipital amyloid may be a risk factor for ARIA-E. #alzheimersdisease

Using brain tissue obtained during surgery for normal pressure hydrocephalus, scientists have identified cell changes due to early AD pathology. The findings could help explain what happens as AD progresses. @UniEastFinland @broadinstitute

Plasma p-tau217 is changing diagnostic testing for Alzheimer’s. Primary care doctors are using it. A startup can speed up clinical workups with in-home testing. Many clinicians are not yet on board. @Memorial_Owosso @ucl @ClevelandClinic @lunduniversity

A blood test for phospho-tau217 could be used to help diagnose AD. In real-world cohorts, the marker distinguishes AD from other dementias, and predicts worsening tau pathology and cognitive decline. @amsterdamumc @ucl @goteborgsuni @stonybrooku @ATRI_USC

New data at AAIC 2025 show that inflammation and AD risk genes shape microglia–neuron connections via nanotubes.

Africa’s first sizeable biomarker and genetics datasets for Alzheimer’s are on the way. Scientists across sub-Saharan Africa are joining forces to collect samples for analysis.

An AI consortium called C-brAIn has officially started. It aims to build an “AI biomedical scientist” to speed discovery in AD research.

A new generation of brain shuttles that use receptors other than TfR, or in addition to it, are making preclinical headway, as reported at #AAIC25.

At AAIC, trontinemab’s near-final 3.6 mg/kg Phase 2 data showed extensive plaque clearance in six months, mostly sans ARIA. Phase 3 to start this fall. #alzheimersdisease

Microglia damage axons connecting Locus coeruleus axons to the olfactory bulb. Is this why smell fades so early on in Alzheimer’s? @LMU_Muenchen

On lecanemab, #alzheimersdisease patients declined a bit less than expected based on their personalized disease trajectory. @Penn @Columbia

Until recently, clinicians used CSF and PET to confirm a positive blood test for AD. Now plasma tests alone are just as accurate, if not better, scientists say. @Wustl @Lunduniversity @UCSF

AD scientists are still confronting rapid change and disruption or their NIH funding. Some grants are restored, others are not. NIH budget cuts were averted, but a new policy tightens purse strings on new awards.

Isoforms of phospho-tau made only in the brain can be found in blood. Immunoassays for these forms better track with Alzheimer’s pathology than those that also detect systemic tau fragments. @ucl @ubc

Isoforms of phospho-tau made only in the brain can be found in blood. Immunoassays for these forms better track with Alzheimer’s pathology than those that also detect systemic tau fragments. @ucl @ubc

Lithium orotate may protect the brain from Alzheimer’s and aging by reducing plaques, tau, and inflammation. Could this old mood stabilizer open a new door for neuroprotection? @harvardmed

In the Tau NexGen trial, six months on lecanemab cleared plaque in symptomatic mutation carriers as well as it does in late-onset #alzheimersdisease. @wustl

U.S. POINTER confirms that lifestyle change can boost cognition in older adults.

Long-term extension studies of lecanemab and donanemab support the idea that amyloid immunotherapy slows #alzheimersdisease. @Yale

A new multiomic approach merges transcriptomic and epigenomic data, yielding the clearest picture yet of cerebrovascular gene networks. Neurodegeneration and vascular disease follow distinct molecular paths. @UCSF